[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lung-function-testing\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lung-function-testing":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":33,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":5},"100654869","assessment-of-lung-function-lufu-at-sea-level-la-vs-high-altitude-ha-in-patients-with-pulmonary-arterial-hypertension-pah-100654869",false,"NCT07804576","Assessment of Lung Function (Lufu) at Sea Level LA vs. High Altitude HA in Patients With Pulmonary Arterial Hypertension PAH","Effect of a One-week Descent From 2850m to Sea Level and Re-ascent in Patients With Pulmonary Arterial Hypertension and Healthy Controls Permanently Living > 2600m on Pulmonary Hemodynamics, Exercise Capacity, Blood Oxygenation, Sleep Disordered Breathing and Further Outcomes","Inclusion Criteria:\n\n* Adult patients aged 18-80 years and of all genders\n* Permanent residence \\> 2600 m\n* Diagnosis of pulmonary arterial hypertension PAH (PAHHA-Group) according to guidelines\n* Patients are stable on therapy\n* NYHA (new york heart association) functional class I-III.\n* written informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Age \\\u003C18 years or \\>80 years\n* unstable condition\n* Patients who cannot follow the study investigations\n* Patient permanently living \\\u003C 2600m.\n* Patients who traveled and stayed overnight at altitudes \\\u003C2000 m in the past 4 weeks.\n* Patients with moderate to severe concomitant lung disease (FEV1\\\u003C70% or forced vital capacity \\\u003C70%), severe parenchymal lung disease, severe smokers (\\>20 cigarettes\u002Fday)\n* Severely hypoxemic patients at Quito permanently having persistent SpO2 (oxygen saturation by pulseoximetry) \\\u003C80% on ambient air.\n* Patient with a non-corrected ventricular septum defect\n* Relevant concomitant other disease of the heart, kidney, liver, blood (anemia hemoglobin\\\u003C11 g\u002Fdl)","ALL","18 Years","80 Years",{"count":20,"type":21},20,"ESTIMATED","INTERVENTIONAL",[24],"NA","To study the effect of a re-ascent to high altitude (Quito Ecuador: 2850m) after a one-week stay at sea level (after prior descent from 2850m) on lung function and pulmonary resistance\u002Freactance in patients with pulmonary arterial disease PAH, who live permanently \\> 2600m.",[27,28,29,30,31,32],"Pulmonary Arterial Hypertension (PAH)","Pulmonary Vascular Disease","High Altitude Effects","High Altitude","Lung Function Testing","Lung Function Changes",[34,35,30,36,37],"Pulmonary arterial hypertension PAH","Pulmonary vascular disease","Lung function","forced oscillation technique","NOT_YET_RECRUITING","2026-08-31",{"date":41,"type":42},"2026-09-04","ACTUAL",{"date":44,"type":21},"2026-09-25",{"date":46,"type":21},"2026-12-31",{"name":48,"class":49},"Silvia Ulrich Somaini","OTHER"]